Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis Diagnosis and Management
Am. j. respir. crit. care med
; 194(6): 748-761, September 15, 2016.
Article
in English
| BIGG - GRADE guidelines
| ID: biblio-966014
Responsible library:
BR1.1
ABSTRACT
"BACKGROUND:
Lymphangioleiomyomatosis (LAM) is a rare cystic lung disease that primarily affects women. The purpose of these guidelines is to provide recommendations for the diagnosis and treatment of LAM.METHODS:
Systematic reviews were performed to summarize evidence pertinent to our questions. The evidence was summarized and discussed by a multidisciplinary panel. Evidence-based recommendations were then formulated, written, and graded using the Grading of Recommendations, Assessment, Development, and Evaluation approach.RESULTS:
After considering the panel's confidence in the estimated effects, the balance of desirable (i.e., benefits) and undesirable (i.e., harms and burdens) consequences of treatment, patient values and preferences, cost, and feasibility, recommendations were formulated for or against specific interventions. These included recommendations for sirolimus treatment and vascular endothelial growth factor D testing and recommendations against doxycycline and hormonal therapy.CONCLUSIONS:
Evidence-based recommendations for the diagnosis and treatment of patients with LAM are provided. Frequent reassessment and updating will be needed."
Full text:
Available
Collection:
Tematic databases
Database:
BIGG - GRADE guidelines
Main subject:
Lymphangioleiomyomatosis
Type of study:
Diagnostic study
/
Practice guideline
Language:
English
Journal:
Am. j. respir. crit. care med
Year:
2016
Document type:
Article